Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 140

Similar articles for PubMed (Select 23478294)

1.

Early estrogen-induced gene 1, a novel RANK signaling component, is essential for osteoclastogenesis.

Choi HK, Kang HR, Jung E, Kim TE, Lin JJ, Lee SY.

Cell Res. 2013 Apr;23(4):524-36. doi: 10.1038/cr.2013.33. Epub 2013 Mar 12.

2.

Targeted inhibition of phospholipase C γ2 adaptor function blocks osteoclastogenesis and protects from pathological osteolysis.

Decker C, Hesker P, Zhang K, Faccio R.

J Biol Chem. 2013 Nov 22;288(47):33634-41. doi: 10.1074/jbc.M113.477281. Epub 2013 Sep 30.

3.

Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.

Takatsuna H, Asagiri M, Kubota T, Oka K, Osada T, Sugiyama C, Saito H, Aoki K, Ohya K, Takayanagi H, Umezawa K.

J Bone Miner Res. 2005 Apr;20(4):653-62. Epub 2004 Dec 6.

PMID:
15765185
4.

Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.

Kim SD, Kim HN, Lee JH, Jin WJ, Hwang SJ, Kim HH, Ha H, Lee ZH.

Biochem Pharmacol. 2013 Sep 15;86(6):782-90. doi: 10.1016/j.bcp.2013.07.015. Epub 2013 Aug 6.

PMID:
23928189
5.

Molecular basis of requirement of receptor activator of nuclear factor κB signaling for interleukin 1-mediated osteoclastogenesis.

Jules J, Zhang P, Ashley JW, Wei S, Shi Z, Liu J, Michalek SM, Feng X.

J Biol Chem. 2012 May 4;287(19):15728-38. doi: 10.1074/jbc.M111.296228. Epub 2012 Mar 13.

7.

Arctigenin suppresses receptor activator of nuclear factor κB ligand (RANKL)-mediated osteoclast differentiation in bone marrow-derived macrophages.

Kim AR, Kim HS, Lee JM, Choi JH, Kim SN, Kim do K, Kim JH, Mun SH, Kim JW, Jeon HS, Kim YM, Choi WS.

Eur J Pharmacol. 2012 May 5;682(1-3):29-36. doi: 10.1016/j.ejphar.2012.02.026. Epub 2012 Feb 24.

PMID:
22387094
8.

Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.

Li C, Yang Z, Li Z, Ma Y, Zhang L, Zheng C, Qiu W, Wu X, Wang X, Li H, Tang J, Qian M, Li D, Wang P, Luo J, Liu M.

J Bone Miner Res. 2011 Mar;26(3):644-56. doi: 10.1002/jbmr.242.

PMID:
20814972
9.

Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation.

Ikeda F, Nishimura R, Matsubara T, Tanaka S, Inoue J, Reddy SV, Hata K, Yamashita K, Hiraga T, Watanabe T, Kukita T, Yoshioka K, Rao A, Yoneda T.

J Clin Invest. 2004 Aug;114(4):475-84.

10.

Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells.

Lee JW, Iwahashi A, Hasegawa S, Yonezawa T, Jeon WB, Cha BY, Nagai K, Woo JT.

J Nat Med. 2012 Jan;66(1):8-16. doi: 10.1007/s11418-011-0537-7. Epub 2011 Jun 9.

PMID:
21656335
11.

Serum calcium-decreasing factor, caldecrin, inhibits osteoclast differentiation by suppression of NFATc1 activity.

Hasegawa H, Kido S, Tomomura M, Fujimoto K, Ohi M, Kiyomura M, Kanegae H, Inaba A, Sakagami H, Tomomura A.

J Biol Chem. 2010 Aug 13;285(33):25448-57. doi: 10.1074/jbc.M109.068742. Epub 2010 Jun 14.

12.

PLCgamma2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2.

Mao D, Epple H, Uthgenannt B, Novack DV, Faccio R.

J Clin Invest. 2006 Nov;116(11):2869-79. Epub 2006 Oct 19.

13.

The transmembrane adaptor protein, linker for activation of T cells (LAT), regulates RANKL-induced osteoclast differentiation.

Kim K, Kim JH, Moon JB, Lee J, Kwak HB, Park YW, Kim N.

Mol Cells. 2012 Apr;33(4):401-6. doi: 10.1007/s10059-012-0009-2. Epub 2012 Feb 28.

14.

Oleanolic acid acetate inhibits osteoclast differentiation by downregulating PLCγ2-Ca(2+)-NFATc1 signaling, and suppresses bone loss in mice.

Kim JY, Cheon YH, Oh HM, Rho MC, Erkhembaatar M, Kim MS, Lee CH, Kim JJ, Choi MK, Yoon KH, Lee MS, Oh J.

Bone. 2014 Mar;60:104-11. doi: 10.1016/j.bone.2013.12.013. Epub 2013 Dec 17.

PMID:
24361669
15.

SC-19220, antagonist of prostaglandin E2 receptor EP1, inhibits osteoclastogenesis by RANKL.

Tsujisawa T, Inoue H, Nishihara T.

J Bone Miner Res. 2005 Jan;20(1):15-22. Epub 2004 Oct 18.

PMID:
15619665
16.

Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.

Lee JH, Jin H, Shim HE, Kim HN, Ha H, Lee ZH.

Mol Pharmacol. 2010 Jan;77(1):17-25. doi: 10.1124/mol.109.057877. Epub 2009 Oct 14.

17.

BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.

Valverde P, Tu Q, Chen J.

J Bone Miner Res. 2005 Sep;20(9):1669-79. Epub 2005 May 16.

PMID:
16059638
18.

A unique domain in RANK is required for Gab2 and PLCgamma2 binding to establish osteoclastogenic signals.

Taguchi Y, Gohda J, Koga T, Takayanagi H, Inoue J.

Genes Cells. 2009 Nov;14(11):1331-45. doi: 10.1111/j.1365-2443.2009.01351.x. Epub 2009 Oct 20.

PMID:
19845770
19.

Siglec-15 protein regulates formation of functional osteoclasts in concert with DNAX-activating protein of 12 kDa (DAP12).

Ishida-Kitagawa N, Tanaka K, Bao X, Kimura T, Miura T, Kitaoka Y, Hayashi K, Sato M, Maruoka M, Ogawa T, Miyoshi J, Takeya T.

J Biol Chem. 2012 May 18;287(21):17493-502. doi: 10.1074/jbc.M111.324194. Epub 2012 Mar 26.

20.

Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis.

Kimachi K, Kajiya H, Nakayama S, Ikebe T, Okabe K.

Naunyn Schmiedebergs Arch Pharmacol. 2011 Mar;383(3):297-308. doi: 10.1007/s00210-010-0596-4. Epub 2011 Jan 12.

PMID:
21225243
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk